A 62-year-old man with benign prostatic hyperplasia (BPH) and hypertension has been on doxazosin 4 mg daily for 3 months with good symptom relief and blood pressure control (BP 135/82 mmHg). He now presents with erectile dysfunction and retrograde ejaculation. His urinalysis and renal function are normal. He asks if there is an alternative alpha blocker that would preserve sexual function while maintaining BPH symptom control. Which of the following is the BEST choice?

Explanation

## Sexual Dysfunction with Alpha Blockers: Mechanism and Management ### Pathophysiology of Sexual Dysfunction with Non-Selective Alpha Blockers **Key Point:** Non-selective α1 antagonists (doxazosin, terazosin) block α1B receptors on vascular smooth muscle in the corpora cavernosa and inhibit sympathetic-mediated ejaculation, leading to: - **Erectile dysfunction** (via α1B blockade in penile vasculature) - **Retrograde ejaculation** (via α1A blockade in bladder neck smooth muscle) ### Uroselective Alpha Blockers: Mechanism of Sexual Preservation **High-Yield:** Uroselective α1A antagonists (tamsulosin, alfuzosin) preferentially block α1A receptors in the prostate and bladder neck while sparing α1B receptors in penile vasculature. This results in: - Preserved erectile function - Reduced incidence of retrograde ejaculation - Maintained BPH symptom relief ### Comparative Incidence of Sexual Dysfunction | Alpha Blocker | Type | α1A Selectivity | Erectile Dysfunction | Retrograde Ejaculation | Mechanism | | --- | --- | --- | --- | --- | --- | | **Doxazosin** | Non-selective | No | 3–5% | 5–8% | Blocks α1B in corpora cavernosa and α1A in bladder neck | | **Terazosin** | Non-selective | No | 3–5% | 5–8% | Same as doxazosin | | **Tamsulosin** | Uroselective | Yes (α1A) | <1% | 1–2% | Spares α1B in penile vasculature | | **Alfuzosin** | Uroselective | Yes (α1A) | <1% | 1–2% | Spares α1B in penile vasculature | **Clinical Pearl:** Tamsulosin has the **lowest incidence of sexual dysfunction** among alpha blockers due to its high α1A selectivity (>260:1 ratio for α1A:α1B). ### Why Switch Rather Than Add Sildenafil? **Key Point:** While sildenafil can be added to any alpha blocker, the **preferred approach** is to switch to a uroselective agent because: 1. Removes the underlying cause of dysfunction (α1B blockade) 2. Avoids polypharmacy and drug interactions 3. Maintains BPH symptom control without sexual side effects 4. Cost-effective and evidence-based ### Mnemonic **Mnemonic:** **"TAME" = Tamsulosin, Alfuzosin = Minimal erectile dysfunction, Uroselective** - **T**amsulosin → **T**est-sparing (sexual function preserved) - **A**lfuzosin → **A**void sexual dysfunction - Non-selective agents → **N**eed to switch if sexual dysfunction occurs ### Treatment Algorithm ```mermaid flowchart TD A[Patient on non-selective α1 blocker<br/>with sexual dysfunction]:::outcome --> B{Symptom control<br/>adequate?}:::decision B -->|Yes| C[Switch to uroselective<br/>α1A blocker]:::action B -->|No| D[Increase dose of<br/>non-selective agent]:::action C --> E[Tamsulosin 0.4 mg<br/>or Alfuzosin 2.5 mg]:::action D --> F[Monitor for worsening<br/>sexual dysfunction]:::action E --> G[Reassess in 4–6 weeks]:::action G --> H[Sexual function<br/>preserved?]:::decision H -->|Yes| I[Continue uroselective agent]:::outcome H -->|No| J[Add PDE5 inhibitor<br/>or consider 5-ARI]:::action ```